Ozempic, Wegovy, and related GLP-1 medicines are approved for specific metabolic indications, not as migraine treatments. Yet people taking them are asking an important question: could a GLP-1 medicine change migraine frequency, either for better or worse?
The honest answer in 2026 is interesting but unsettled. A medicine can affect migraine indirectly through weight, glucose regulation, appetite, hydration, sleep, and gastrointestinal symptoms. That does not prove it treats migraine itself.
What the early evidence says
A 2026 Danish register study found a modest reduction in triptan use during the year after people started semaglutide. This was an observational study, so it cannot establish that semaglutide caused fewer migraine attacks. Changes in weight, health care use, diabetes control, other medicines, or the reasons people started semaglutide may have contributed.
A systematic review found that GLP-1 biology is relevant to pain and headache research, but the evidence for using GLP-1 receptor agonists to treat migraine remains limited. A small case series and real-world studies can generate useful hypotheses; they do not replace randomized migraine trials.
Why headaches may improve for some people
Several pathways are plausible, but plausibility is not proof:
- Weight reduction may help some people whose migraine is affected by obesity or sleep-disordered breathing.
- More stable eating patterns may reduce attacks linked to skipped meals or fasting.
- Treating diabetes or insulin resistance may change overall metabolic stress.
- Fewer migraine days may occur when sleep, movement, or another health condition improves at the same time.
These possibilities should not be turned into a promise that a GLP-1 medicine will prevent migraine. It should also not be used solely for migraine without a clinician deciding that the medication is appropriate for its approved indication.
Why a GLP-1 medicine may trigger or worsen a headache
Headache is listed among common adverse reactions for Wegovy. Nausea, vomiting, diarrhea, reduced food intake, and dehydration can also make an existing migraine pattern harder to manage. Some people may be more sensitive during dose increases or when they are eating much less than usual.
If a new headache starts after a medication change, record the timing rather than assuming the medicine is the only cause. An attack may also reflect missed meals, dehydration, a disrupted sleep schedule, illness, caffeine change, or another medication.
What to track before a medication conversation
| Field | What to record |
|---|---|
| Baseline migraine days | A few weeks before the medication change, if available |
| Injection date and dose change | Include the first dose and each increase |
| Headache timing | When symptoms began relative to the dose |
| Food and fluids | Missed meals, vomiting, diarrhea, and hydration |
| Acute medicine use | Medicine, time taken, response, and recurrence |
| Weight and glucose data | Only if your clinician has recommended monitoring |
| Other changes | Sleep, caffeine, stress, illness, and new medicines |
Do not start, stop, compound, share, or change the dose of a GLP-1 medicine based on a migraine article. Talk with the prescriber and pharmacist, especially if you have diabetes, kidney disease, gallbladder disease, severe gastrointestinal symptoms, or are pregnant or planning pregnancy.
When a headache needs urgent care
Seek urgent help for a sudden “worst” headache, new weakness, confusion, fainting, persistent vision loss, severe dehydration, repeated vomiting, or a headache with fever and a stiff neck. Those symptoms need assessment regardless of whether a GLP-1 medicine was recently started.
For now, the most useful conclusion is simple: GLP-1 medicines may be relevant to migraine research, but they are not established migraine preventives. Use a dated symptom record to help your clinician separate a possible medication effect from the many other variables that change migraine.
Related Resources
This article is educational and is not a substitute for individual medical advice.
Sources
